These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 18007196

  • 1. Mu opioid receptor mutant, T394A, abolishes opioid-mediated adenylyl cyclase superactivation.
    Wang H, Guang W, Barbier E, Shapiro P, Wang JB.
    Neuroreport; 2007 Dec 03; 18(18):1969-73. PubMed ID: 18007196
    [Abstract] [Full Text] [Related]

  • 2. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
    Szücs M, Boda K, Gintzler AR.
    J Pharmacol Exp Ther; 2004 Jul 03; 310(1):256-62. PubMed ID: 14996951
    [Abstract] [Full Text] [Related]

  • 3. Adenylyl cyclase superactivation induced by long-term treatment with opioid agonist is dependent on receptor localized within lipid rafts and is independent of receptor internalization.
    Zhao H, Loh HH, Law PY.
    Mol Pharmacol; 2006 Apr 03; 69(4):1421-32. PubMed ID: 16415176
    [Abstract] [Full Text] [Related]

  • 4. Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment.
    Varga EV, Rubenzik MK, Stropova D, Sugiyama M, Grife V, Hruby VJ, Rice KC, Roeske WR, Yamamura HI.
    J Pharmacol Exp Ther; 2003 Jul 03; 306(1):109-15. PubMed ID: 12660310
    [Abstract] [Full Text] [Related]

  • 5. Plasticity of adenylyl cyclase-related signaling sequelae after long-term morphine treatment.
    Shy M, Chakrabarti S, Gintzler AR.
    Mol Pharmacol; 2008 Mar 03; 73(3):868-79. PubMed ID: 18045853
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
    Clark MJ, Traynor JR.
    J Pharmacol Exp Ther; 2005 Feb 03; 312(2):809-15. PubMed ID: 15383633
    [Abstract] [Full Text] [Related]

  • 8. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain.
    Chaipatikul V, Loh HH, Law PY.
    J Pharmacol Exp Ther; 2003 Jun 03; 305(3):909-18. PubMed ID: 12626655
    [Abstract] [Full Text] [Related]

  • 9. Opioid mu receptor activation inhibits sodium currents in prefrontal cortical neurons via a protein kinase A- and C-dependent mechanism.
    Witkowski G, Szulczyk P.
    Brain Res; 2006 Jun 13; 1094(1):92-106. PubMed ID: 16733049
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons.
    Rodríguez-Muñoz M, de la Torre-Madrid E, Gaitán G, Sánchez-Blázquez P, Garzón J.
    Cell Signal; 2007 Dec 13; 19(12):2558-71. PubMed ID: 17825524
    [Abstract] [Full Text] [Related]

  • 12. T394A Mutation at the μ Opioid Receptor Blocks Opioid Tolerance and Increases Vulnerability to Heroin Self-Administration in Mice.
    Wang XF, Barbier E, Chiu YT, He Y, Zhan J, Bi GH, Zhang HY, Feng B, Liu-Chen LY, Wang JB, Xi ZX.
    J Neurosci; 2016 Oct 05; 36(40):10392-10403. PubMed ID: 27707973
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chronic morphine treatment increases stimulatory beta-2 adrenoceptor signaling in A431 cells stably expressing the mu opioid receptor.
    Ammer H, Schulz R.
    J Pharmacol Exp Ther; 1997 Jan 05; 280(1):512-20. PubMed ID: 8996236
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adenylyl cyclase type II activity is regulated by two different mechanisms: implications for acute and chronic opioid exposure.
    Schallmach E, Steiner D, Vogel Z.
    Neuropharmacology; 2006 Jun 05; 50(8):998-1005. PubMed ID: 16545401
    [Abstract] [Full Text] [Related]

  • 17. Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.
    Clayton CC, Bruchas MR, Lee ML, Chavkin C.
    Mol Pharmacol; 2010 Mar 05; 77(3):339-47. PubMed ID: 19959593
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization.
    Clark MJ, Neubig RR, Traynor JR.
    J Pharmacol Exp Ther; 2004 Jul 05; 310(1):215-22. PubMed ID: 15014136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.